Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Tan Tock Seng Hospital
- Registration Number
- NCT04764097
EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT04743453
- Locations
- 🇧🇷
Hospital das Clinicas - FMUSP, Sao Paulo, Brazil
Dapagliflozin (DAPA) Effects in HFpEF
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT04730947
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 542
- Registration Number
- NCT04724837
- Locations
- 🇺🇦
Research Site, Zhytomyr, Ukraine
Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Xiangtan Central Hospital
- Target Recruit Count
- 1990
- Registration Number
- NCT04707261
- Locations
- 🇨🇳
Xiangtan Central Hospital, Xiangtan, Hunan, China
A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Kyung Hee University Hospital at Gangdong
- Target Recruit Count
- 120
- Registration Number
- NCT04706637
- Locations
- 🇰🇷
The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Inha University Hospital, Incheon, Korea, Republic of
🇰🇷Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-07-12
- Target Recruit Count
- 162
- Registration Number
- NCT04707352
- Locations
- 🇪🇸
Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain
SGLT2-Inhibitors for Sleep Apnea in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Columbia University
- Registration Number
- NCT04640493
- Locations
- 🇺🇸
Vivian and Seymour Milstein Family Heart Center, New York, New York, United States
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 200
- Registration Number
- NCT04634500
- Locations
- 🇰🇷
Daewoong pharmatceutical, Soeul, Korea, Republic of
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 153
- Registration Number
- NCT04595370
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.